The Federal Circuit in its precedential decision in Phigenix v ImmunoGen has ruled the petitioner lacked standing to appeal a Patent Trial and Appeal Board final written decision because of insufficient evidence to show an “injury-in-fact”
Unlock this content.
The content you are trying to view is exclusive to our subscribers.
Leaders at the IP firms, which have joined forces with backing from a PE investor, share their vision of building the number one pan-European IP practice
The opinion provides useful guidance when it comes to how courts might consider contributory infringement, DMCA claims, and other issues in AI copyright cases